Advances in NK cell therapy for multiple myeloma

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2025-05-28 DOI:10.1016/j.beha.2025.101639

Najing Liu , Yujin Zeng , Ying Wang , Congyue Wang , Nuoxian Li , Jinge Xu

引用次数: 0

Abstract

Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally. In patients with MM, the number and function of NK cells are suppressed, resulting in reduced immune surveillance and clearance of myeloma cells. Restoring or enhancing the killing effect of NK cells on myeloma cells is an important strategy for MM immunotherapy. At present, a series of great progress has been made in preclinical and clinical studies for NK cell adoptive therapy and CAR-NK therapy. This article introduces the current status of various treatment strategies for MM, NK cells in MM, and reviews the latest results of NK cell immunotherapy for MM.

查看原文本刊更多论文

NK细胞治疗多发性骨髓瘤的进展

多发性骨髓瘤（MM）是一种克隆性浆细胞异常增殖的恶性疾病。在MM患者中，NK细胞的数量和功能受到抑制，导致免疫监视和骨髓瘤细胞清除减少。恢复或增强NK细胞对骨髓瘤细胞的杀伤作用是骨髓瘤免疫治疗的重要策略。目前，NK细胞过继疗法和CAR-NK疗法在临床前和临床研究方面取得了一系列重大进展。本文介绍了MM的各种治疗策略的现状，MM中的NK细胞，并综述了NK细胞免疫治疗MM的最新成果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.